Nakamura 2001.

Methods	Study design: parallel RCT Study time frame: not reported Duration of follow‐up: 3 months
Participants	Country: Japan Setting: not reported Inclusion criteria: dialysis patients with type 2 DM, dyslipidaemia without lipid lowering drugs Number: treatment group (10); control group (10) Mean age: 54.5 years (age not reported for each group) Sex (M/F): 12/8 (sex not reported for each group) Exclusion criteria: not reported
Interventions	Treatment group Pioglitazone: 30 mg/d Control group Placebo
Outcomes	HbA1c levels Fasting serum triglyceride levels Fasting HDL cholesterol levels Fasting total cholesterol levels
Notes	Written to authors for data for inclusion in the meta‐analysis. No data available Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients were given a placebo tablet
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients discontinued
Selective reporting (reporting bias)	Unclear risk	The prespecified outcomes were not available on a clinical trials database
Other bias	Unclear risk	Conflicts of interest were not reported